Current therapies to treat opportunistic infections associated with the Acquired Immunodeficiency Syndrome (AIDS) are either highly toxic, extremely expensive or marginally effective. Since these infections produce significant morbidity and mortality in patients with AIDS, the National Institute of Allergy and Infectious Diseases facilitates discovery and development of novel therapies for the treatment of AIDS-related opportunistic infections. This includes providing contract resources for identifying and developing potential new drugs, and conducting efficacy evaluations in animal models, a critical component in the drug approval process. At present there is no recommended therapy for infection with Cryptosporidium parvum, in part, because of the lack of in vitro culture systems and small animal models that are suitable for drug evaluations. Phase 1 of this project will support three agencies in the development of in vitro and in vivo test systems. Thereafter in Phase 2 of the program, one or more of these agencies will be selected to apply their systems toward evaluating the efficacy of potential new drugs against Cryptosporidium. The culture systems and animal models developed through these contracts will therefore provide NIAID with the necessary resources to provide critical support for investigator-initiated drug discovery, to stimulate private sector sponsorship of compounds with demonstrated efficacy, and to select the best drug candidates for clinical trials. Phase 1 of the contract indicated above will adapt the SCID mouse for in vivo screening of candidate therapies against Cryptosporidium infection. Criteria for evaluating the impact of pharmacologic agents include: oocyst shedding, tissue colonization (distribution and intensity) and clinical signs. The SCID mouse model will be further adapted to evaluate agents in a 4-tiered assay protocol employing 1) a prophylactic model, 2) a chronic model, 3) a terminal/disseminated model, and 4) a relapsing/recurrent model. If selected for Phase 2 of the program, the contractor will 1) systematically apply their animal model toward drug evaluations 2) develop a reproducible, quantitative model of C. parvum cultivation in vitro, and 3) apply the culture assays to initially screen compounds for further testing-in the SCID model.

Project Start
1992-07-07
Project End
1996-07-06
Budget Start
1994-09-27
Budget End
1995-11-06
Support Year
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Emory University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
You, X; Schinazi, R F; Arrowood, M J et al. (1998) In-vitro activities of paromomycin and lasalocid evaluated in combination against Cryptosporidium parvum. J Antimicrob Chemother 41:293-6
Benbow, J W; Bernberg, E L; Korda, A et al. (1998) Synthesis and evaluation of dinitroanilines for treatment of cryptosporidiosis. Antimicrob Agents Chemother 42:339-43
You, X; Arrowood, M J; Lejkowski, M et al. (1996) A chemiluminescence immunoassay for evaluation of Cryptosporidium parvum growth in vitro. FEMS Microbiol Lett 136:251-6
You, X; Arrowood, M J; Lejkowski, M et al. (1996) In vitro evaluation of anticryptosporidial agents using MDCK cell culture and chemiluminescence immunoassay. J Eukaryot Microbiol 43:87S
Arrowood, M J; Mead, J R; Xie, L et al. (1996) In vitro anticryptosporidial activity of dinitroaniline herbicides. FEMS Microbiol Lett 136:245-9
Arrowood, M J; Hurd, M R; Mead, J R (1995) A new method for evaluating experimental cryptosporidial parasite loads using immunofluorescent flow cytometry. J Parasitol 81:404-9
Mead, J R; You, X; Pharr, J E et al. (1995) Evaluation of maduramicin and alborixin in a SCID mouse model of chronic cryptosporidiosis. Antimicrob Agents Chemother 39:854-8
Mead, J R; Ilksoy, N; You, X et al. (1994) Infection dynamics and clinical features of cryptosporidiosis in SCID mice. Infect Immun 62:1691-5